Boston Scientific paid $1.5 billion for a roughly 34% stake in MiRus and an option to acquire the SIEGEL TAVR business, a potential fast path back into balloon‑expandable valves. The move hinges on clinical and regulatory milestones.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

LSU LCMC Health Cancer Center is expanding clinical trials and precision oncology in New Orleans, adding early‑phase cellular studies and new specialists.

A JAMA Cardiology study led by UT Southwestern shows an AI‑augmented ECG screened nearly 6,000 Kenyans and reliably ruled out left‑ventricular dysfunction for most patients.

Dexcom’s investor day laid out product and reimbursement milestones that local analysts say could channel roughly $800M into San Diego through 2030. The plan hinges on G8 performance, Medicare coverage and broader adoption.

Philanthropist Lynde B. Uihlein gave $10 million to UWM's School of Freshwater Sciences to fund research, water policy and upkeep for research vessels.

UH researchers helped lead a team that identified blood‑based RNA markers for inflammatory breast cancer, pointing to less invasive diagnosis and monitoring. The study appears in Science Advances.

A UC Berkeley working paper ties a post‑ChatGPT surge in A grades to students’ use of generative AI. Campuses are redesigning exams and reinstating proctoring to protect degree value.

Martha Stewart has co‑founded Hint, a Charlotte AI home‑management startup that raised $10M and plans a summer launch to help homeowners spot problems early.

New York’s cannabis regulator has launched a pilot observational study testing oral THC and CBD for adults with inflammatory bowel disease, partnering with licensed dispensaries.

Schwab says AI is boosting efficiency, but surging accounts and assets have the firm adding staff in Texas and at its Westlake campus.

Biogen will advance diranersen — an antisense tau drug given intrathecally — to late‑stage trials after a Phase 2 readout showed tau reduction and hints of slowed decline.

OpenAI is weighing legal steps against Apple after reporting says its ChatGPT tie‑in with Siri hasn’t delivered as promised.